{"id":4614,"date":"2025-03-31T18:12:14","date_gmt":"2025-03-31T18:12:14","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/papaveretum-txt\/"},"modified":"2025-03-31T18:12:14","modified_gmt":"2025-03-31T18:12:14","slug":"papaveretum-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/papaveretum-txt\/","title":{"rendered":"papaveretum.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nOpiate analgesia

DOSE IN NORMAL RENAL FUNCTION <\/H3>SC\/IM: 0.5\u20131 mL every 4 hoursIV: 25\u201350% of dose

PHARMACOKINETICS <\/H3>Papaverine Morphine Codeine Molecular weight (daltons)375.8375.8371.9% Protein binding9020\u2013357% Excreted unchanged in urine<110<5Volume of distribution (L\/kg)0.99\u20131.52 3\u201353\u20134half-life \u2013 normal\/ESRD (hrs)1.2\u20132.2\/\u2013 2\u20133\/ Un-changed2.5\u20134\/\u2013

DOSE IN RENAL IMPAIRMENT <\/H3>

GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : 0.4\u20130.75 mL every 6\u20138 hours
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 0.25\u20130.5 mL every 6\u20138 hours. Avoid if possible

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unlikely to be dialysed. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anti-arrhythmics: delayed absorption of mexiletine\n
  • Antidepressants: possible CNS excitation or depression with MAOIs \u2013 avoid concomitant use; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics\n
  • Antivirals: concentration possibly increased with ritonavirSodium oxybate: enhanced effect of sodium oxybate \u2013 avoid concomitant use

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>SC, IM, IV

    Rate of Administration <\/H4>IV bolus or continuous infusion (1 mg\/mL)

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>As with all opiates, use with extreme caution in patients with impaired renal functionMay cause excessive sedation and respiratory depressionPapaveretum 15.4 mg =1 mL \u2261 10 mg morphine.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Opiate analgesia DOSE IN NORMAL RENAL FUNCTION SC\/IM:<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4614","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4614"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4614\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}